When.com Web Search

  1. Ads

    related to: fda approved colorectal cancer treatment

Search results

  1. Results From The WOW.Com Content Network
  2. US FDA approves Bristol Myers' colorectal cancer therapy

    www.aol.com/news/us-fda-approves-bristol-myers...

    Krazati had received accelerated approval from the FDA in 2022 for the treatment of a type of advanced lung cancer with the mutated form of the gene known as KRAS.

  3. Cetuximab - Wikipedia

    en.wikipedia.org/wiki/Cetuximab

    Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .

  4. Pembrolizumab - Wikipedia

    en.wikipedia.org/wiki/Pembrolizumab

    In June 2020, the US FDA approved a new indication for pembrolizumab as the first-line treatment for people with unresectable or metastatic microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) colorectal cancer. [17] The approval marks the first immunotherapy approved for that population in the US as a first-line ...

  5. Bevacizumab - Wikipedia

    en.wikipedia.org/wiki/Bevacizumab

    Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]

  6. MEK inhibitor - Wikipedia

    en.wikipedia.org/wiki/MEK_inhibitor

    Cobimetinib or XL518, approved by US FDA in Nov 2015 for use in combination with vemurafenib (Zelboraf(R)), for treatment of advanced melanoma with a BRAF V600E or V600K mutation. Selumetinib , had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated an improvement in PFS, [ 5 ] and is now in phase III development ...

  7. FDA Clears Exact Sciences' Next-Generation Colorectal Cancer ...

    www.aol.com/fda-clears-exact-sciences-next...

    In July this year, the FDA approved Guardant Health Inc.’s (NASDAQ:GH) Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.

  1. Ads

    related to: fda approved colorectal cancer treatment